Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin&rsquo;s lymphoma

Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin&rsquo;s lymphoma

Christos EmmanouilidesDepartment of Medical Oncology, Interbalkan Hospital, Thessaloniki, GreeceAbstract: Several studies have indicated that radioimmunotherapy is an effective and clinically relevant complementary therapeutic approach for patients with B-cell non-Hodgkin&rsquo;s lymphoma (N...

Full description

Bibliographic Details
Main Author:	Christos Emmanouilides
Format:	Article
Language:	English
Published:	Dove Medical Press 2009-10-01
Series:	Cancer Management and Research
Online Access:	http://www.dovepress.com/review-of-90y-ibritumomab-tiuxetan-as-first-line-consolidation-radio-i-a3657

Similar Items

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
by: McKinney MS, et al.
Published: (2014-08-01)

Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
by: Martina Lehnert, et al.
Published: (2009-07-01)

RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution
by: Marcio Miguel Andrade Campos, et al.
Published: (2012-01-01)

Bulky Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan
by: Shinobu Tamura, et al.
Published: (2013-01-01)

FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by <sup>90</sup>yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases
by: Assisi Daniela, et al.
Published: (2011-02-01)

Dynamic Metabolic Changes during the First 3 Months after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy
by: Miwako Takahashi, et al.
Published: (2014-01-01)

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
by: Michael A. Lane, et al.
Published: (2015-01-01)

Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA)
by: Sarbajit Mukherjee, et al.
Published: (2018-09-01)

Resistance to ibritumomab in lymphoma
by: Lalit Kumar
Published: (2020-01-01)

Update on treatment of follicular non-Hodgkin&rsquo;s lymphoma: focus on potential of bortezomib
by: Brander DM, et al.
Published: (2012-03-01)

Bendamustine in the treatment of non-Hodgkin&rsquo;s lymphomas
by: Fredrick Hagemeister, et al.
Published: (2009-12-01)

Rituximab in the treatment of non-Hodgkin&rsquo;s lymphoma
by: Beate Hauptrock, et al.
Published: (2008-09-01)

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (<sup>111</sup>In)/Yttrium 90 (<sup>90</sup>Y) Ibritumomab Tiuxetan (Zevalin<sup>®</sup>) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
by: Richard L. Wahl, et al.
Published: (2021-06-01)

Nouvelles modalités (consolidation, fractionnement) de radioimmunothérapie par 90Y-ibritumomab tiuxetan ("Zevalin") en traitement de première ligne des lymphomes malin non hodgkinien de type folliculaire: efficacité, toxicité et approche dosimétrique personnalisée
by: Morschhauser, Franck
Published: (2008)

Reduced intensity treatment in early-stage Hodgkin&rsquo;s lymphoma
by: Armitage JO, et al.
Published: (2011-11-01)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin&rsquo;s lymphoma
by: Rudolf Weide
Published: (2008-09-01)

Immunotherapies in Non-Hodgkin’s Lymphoma
by: Christine Bezombes, et al.
Published: (2021-07-01)

mTOR inhibitor in the treatment of Hodgkin&rsquo;s lymphoma: a case report
by: Provencio M., et al.
Published: (2011-11-01)

Allergic conditions are not associated with the risk of non-Hodgkin’s lymphoma or Hodgkin’s lymphoma: a systematic review and meta-analysis
by: Yang J, et al.
Published: (2017-04-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

Cytogenetic and molecular analysis of follicular non-Hodgkin's lymphoma
by: Turner, G. E.
Published: (1992)

Cancer Immunotherapy and the Immune Response in Follicular Lymphoma
by: Frank Stenner, et al.
Published: (2018-06-01)

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
by: Robert Pytlik, et al.
Published: (2020-11-01)

Relapsed and refractory classical Hodgkin lymphoma immunotherapy
by: Kirill Lepik
Published: (2020-10-01)

Newest Approaches in Immunotherapy for Non-Hodgkin’s Lymphoma
by: Emily C. Ayers, et al.
Published: (2018-12-01)

Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma
by: Christoph Renner, et al.
Published: (2018-06-01)

Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin&rsquo;s lymphoma
by: Michael J Burdick, et al.
Published: (2009-08-01)

Composite t(14;18)-Negative Follicular Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma
by: John Patrick O’Neill, et al.
Published: (2018-01-01)

Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
by: Theodoros P. Vassilakopoulos, et al.
Published: (2019-07-01)

Simultaneous occurrence of follicular lymphoma and mixed-cellularity Hodgkin's lymphoma: lymph node and extranodal involvement
by: Grangeiro Maria do Patrocínio F., et al.
Published: (2004-01-01)

Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes
by: Castagna L, et al.
Published: (2020-10-01)

Patterns of Glucose Fluctuation are Challenging in Patients Treated for Non-Hodgkin’s Lymphoma
by: Marić A, et al.
Published: (2020-04-01)

Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy
by: Perna SK, et al.
Published: (2015-03-01)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
by: Simon Hallam
Published: (2018-08-01)

Analisi costi-efficacia di 90Y-ibritumomab tiuxetano (Zevalin®) vs. terapie attualmente disponibili nel trattamento dei pazienti affetti da Linfoma Non-Hodgkin (LNH) refrattario o recidivato
by: Carlo Lazzaro, et al.
Published: (2005-12-01)

How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas
by: Mohammed R, et al.
Published: (2019-02-01)

Clinical significance of bcl-2 protein in the progress of patients with follicular non-Hodgkin lymphoma.
by: ELENI GOVA
Published: (2014-08-01)

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
by: A Boland, et al.
Published: (2009-09-01)

Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
by: Y Dundar, et al.
Published: (2009-06-01)

Single nucleotide polymorphisms of microRNA processing genes and outcome of non-Hodgkin’s lymphoma
by: Gao Y, et al.
Published: (2015-07-01)

Cannot write session to /tmp/vufind_sessions/sess_9d0uht0mdj4nag3frf9uqso9u1